Abstract
Oxaliplatin-induced immune thrombocytopenia (OIIT), which is caused by antibodies that target platelets in the presence of oxaliplatin, is a rare complication of repeated oxaliplatin exposure and oxaliplatin desensitization with high morbidity (bleeding with refractory thrombocytopenia, autoimmune hemolytic anemia in certain patients, and even renal failure in patients with thrombotic microangiopathy). We sought to prevent OIIT complications in patients receiving oxaliplatin desensitization through screening selected patients for drug-dependent antibodies prior to the onset of clinical complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
